Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

AVENuE : Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Male or<br/>FemaleGender Male or

Closed (no longer recruiting)Status Closed (no longer recruiting)


TwoPhase Two

16-60Age 16-60

Blood<br/>CancersCancer LocationBlood

Treatment | Blood / Myeloma / LymphomaHodgkin's Disease (Hodgkin's Lymphoma),Lymphoma

Trial Overview Read MoreRead more

This trial aims to assess the safety and effectiveness of avelumab, a targeted therapy, in patients that are previously untreated for high risk stage 2, stage 3 and stage 4 Hodgkin lymphoma .

This trial is treating patients with Hodgkin Lymphoma.

This is a systemic therapy.

You may be able to join this trial if:

  • You are currently receiving treatment for your cancer.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Commercial Sponsor


Other Non-Commercial Sponsor

University College, London


Eligible patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles. Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab intravenously, every 2 weeks.

Not Recruiting Hospitals Read MoreRead more


Austin Health
Ms Samantha Chakar
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.